Welcome to the CNS 2026 Thematic Conference

Beyond the Prescription:
Single and Dual GLP-1/GIP Receptor Agonists, Nutrition and Health  

Conference co-chairs:

John Sievenpiper, MD, PhD - University of Toronto
Kaberi Dasgupta, MD, MSc - McGill University 

Join us for an engaging and timely one-day conference focused on the intersection of incretin mimetics and nutrition.

Conference Description:

The use of incretin-based therapies—particularly glucagon-like-peptide-1 receptor agonists (GLP-1RA) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists—has surged in recent years, revolutionizing the treatment of obesity and type 2 diabetes. These medications, originally developed to support blood glucose regulation, have demonstrated significant effects on appetite control, weight loss, and cardiometabolic health. As their use expands to broader populations, healthcare professionals are increasingly faced with new challenges related to nutritional adequacy, lean mass preservation, long-term weight management, and equitable access to care.

Join us for an engaging and timely one-day conference focused on the intersection of incretin mimetics and nutrition. This event will explore the physiological and nutritional impacts of GLP1 and GIP therapies, including the risk of muscle loss, weight rebound after discontinuation, and strategies to support diet quality and long-term behaviour change. We will also examine the broader health benefits of these medications—such as cardiovascular and renal protection—and address the ethical and practical considerations of ensuring access and patient-centered care. Featuring leading experts, clinicians, and lived experience perspectives, this conference offers a comprehensive look at the evolving role of nutrition in supporting individuals using these transformative therapies.

CONFERENCE HIGHLIGHTS:

• Expert Speakers: Hear from respected speakers who will present the latest research findings on the physiological, metabolic, and nutritional impacts of incretin-based therapies (GIP and GLP-1 receptor agonists) on diabetes, obesity, and cardiometabolic conditions
• Panel Discussions: Engage with interdisciplinary panels discussing health effects, practical applications, and ethical considerations
• Networking Opportunities: Connect with fellow professionals, researchers, and thought leaders to exchange ideas and foster collaborations.
• Continuing Education: Earn credits to use towards your continuing education activities.

Conference learning objectives: 

By attending this conference, attendees will be able to:

• Describe the physiological effects and clinical applications of GLP1 and GIP receptor agonists in the management of obesity and chronic disease. 
• Evaluate the nutrition and physical activity considerations associated with incretin-based therapies, including diet quality, nutrient adequacy, and the risk of lean mass loss. 
• Discuss strategies to prevent or manage weight regain following the discontinuation of GLP1 and GIP medications. 
• Identify key issues related to equitable access, patient-centered care, and the broader health benefits of GLP1 and GIP receptor agonists beyond weight loss.